08:15 AM EDT, 05/29/2024 (MT Newswires) -- TScan Therapeutics ( TCRX ) said Wednesday it has received the US Food and Drug Administration's Regenerative Medicine Advanced Therapy designation for its blood malignancy treatment candidates TSC-100 and TSC-101.

The company said TSC-100 and TSC-101 are the lead therapy candidates in its heme malignancies program aimed at treating patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation.

The RMAT designation, which speeds up development and review processes, followed an update on the company's phase 1 trial showing that eight patients who received either TSC-100 or TSC-101 remained relapse-free for more than 10 months.

Shares of TScan Therapeutics ( TCRX ) were about 3% higher in recent premarket activity.

Price: 9.00, Change: +0.26, Percent Change: +2.97